Monitor ISS's updated recommendation following this clarification. If dilution concerns are resolved, Proposal 4 is more likely to pass, preserving equity incentive capacity. The vote outcome will be known shortly after June 18, 2026.
Price Chart
Executive Summary
Anika Therapeutics filed a supplement to its proxy statement correcting the disclosure of stock options outstanding under the Sixth Amended 2017 Omnibus Incentive Plan, excluding 476,221 shares underlying stock appreciation rights (SARs) that can be settled in cash. This clarification addresses ISS's unfavorable recommendation on Proposal 4 (approval of the Seventh Amended Plan) by potentially reducing the estimated dilution.
Key Facts
- ISS gave an unfavorable recommendation to the Seventh Amended Plan due to excessive dilution concerns.
- The supplement corrects the table on page 89 of the proxy statement: Stock Options Outstanding of 2,231,740 includes 476,221 shares underlying SARs that may be settled in cash or stock at the company's election.
- The Board unanimously recommends a vote FOR the Seventh Amended Plan.
- Annual Meeting of Stockholders is scheduled for June 18, 2026.
Financial Impact
No financial figures provided; correction may improve ISS recommendation and plan approval chances.
Risk Factors
- Shareholder rejection of the Seventh Amended Plan could limit the company's ability to grant equity awards.
- Continued ISS opposition could sway institutional votes against the plan.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001140361-26-023475 |
| Document: 0001140361-26-023475-index-headers.html | 0001140361-26-023475 |
| Document: 0001140361-26-023475-index.html | 0001140361-26-023475 |
| Document: 0001140361-26-023475.txt | 0001140361-26-023475 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access